ClinicalTrials.gg
Not yet recruitingNCT07939490Updated Nov 16, 2026

JULÄINE™ - Neck Skin Laxity Clinical Investigation

An interventional study of Poly-L-Lactic Acid in Neck Skin Laxity, sponsored by Nordberg Medical AB. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nordberg Medical AB · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study will assess the safety of JULÄINE™, an injectable filler containing poly-L-lactic acid (PLLA), and whether it can improve loose skin on the neck.

The main question is whether more than 60% of treated participants show an improvement of at least one level on a neck skin laxity scale, 26 weeks after their final treatment. Improvement will be measured by comparing neck skin looseness before and after treatment.

The study plans to enroll adults aged 18 years or older with mild to moderately severe loose neck skin at three sites. All participants will receive the filler during three treatment sessions, approximately four weeks apart.

Participation will last approximately 14 months, including screening, treatment, and follow-up until 52 weeks after the final treatment. Investigators will assess changes using standardised photographs, measurements of skin elasticity, and questionnaires about participants' views of their neck appearance. The study will also monitor adverse events through the final follow-up visit.

02

Conditions studied

  • Neck Skin Laxity

Keywords

  • Skin Laxity
  • PLLA
  • Poly-L-lactic acid
  • Neck
  • Neck skin laxity
  • Cervical skin laxity
  • Injectable filler
  • Skin elasticity
  • Skin ageing
03

In context

Lead sponsor

Nordberg Medical AB is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older with mild to moderate-to-severe neck skin laxity (Grade 2-4 on Neck Laxity Scale).
  • Willing to avoid aesthetic procedures involving the neck and lower face and changes to treatments affecting skin quality during the study.
  • If of , a negative pregnancy test and agreement to use highly effective throughout treatment and for eight weeks afterward.
  • Able to provide written and comply with study visits, assessments, and post-treatment instructions.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, breastfeeding, or planned pregnancy or reproductive donation/retrieval procedures during the study or within eight weeks after the final visit.
  • Previous neck surgery or major maxillofacial/cervical surgery; neck injections within 12 months; neck resurfacing or other aesthetic procedures within six months; or planned procedures during the study.
  • Significant neck skin disease, infection, scarring, pigmentation abnormalities, or other conditions interfering with treatment or assessment.
  • Prominent neck muscle bands, excessive facial or neck fat, or anatomy unsuitable for injectable treatment, as assessed by the investigator.
  • Significant thyroid enlargement, uncontrolled thyroid disease, or other unstable endocrine disease.
  • Allergy to device components, coagulation disorders, or anticoagulant/antiplatelet treatment, subject to protocol-defined exceptions.
  • Recent immune-modifying treatment, chemotherapy, or systemic above 10 mg prednisone-equivalent daily; relevant corticosteroid/retinoid use; or treatments affecting collagen production.
  • Hormone replacement therapy or thyroid medication that does not meet protocol-defined stability requirements.
  • Immune deficiency, disease, impaired wound healing, or significant malignant, dermatological, or systemic disease.
  • Significant recent or expected weight changes, recent bariatric surgery, ongoing postoperative weight loss, or active weight-loss treatment, subject to protocol-defined exceptions.
  • Any condition preventing valid or compliance with study requirements.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    JULÄINE™

    Device: Poly-L-Lactic Acid

Interventions

  • DevicePoly-L-Lactic Acid

    JULÄINE™, a poly-L-lactic acid (PLLA)-based injectable filler, administered beneath the skin on both sides of the neck during three treatment sessions, approximately four weeks apart.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Improved Neck Skin Laxity

    Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement.

    Time frame: Baseline and 26 weeks after the final treatment session

Secondary outcomes

  1. Percentage of Participants With Improved Neck Skin Laxity at 12 and 52 Weeks

    Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement.

    Time frame: Baseline and 12 and 52 weeks after the final treatment session

  2. Percentage of Participants With Improved Neck Skin Elasticity

    Percentage of participants showing an increase of at least 10% from baseline in the Cutometer R2 parameter, a measure of overall skin elasticity. Higher R2 values indicate greater elasticity.

    Time frame: Baseline and 26 weeks after the final treatment session

  3. Investigator-Rated Change in Neck Appearance

    Distribution of investigator ratings on the seven-point Global Aesthetic Improvement Scale, ranging from "very much improved" to "very much worse," based on comparisons of standardised post-treatment and baseline photographs.

    Time frame: 12, 26, and 52 weeks after the final treatment session

  4. Change From Baseline in FACE-Q Appraisal of the Neck Score

    Change from baseline in participants' assessment of their neck appearance using the FACE-Q Appraisal of the Neck questionnaire. Raw scores are converted to a score ranging from 0 to 100 using the instrument's scoring algorithm.

    Time frame: Baseline and 12, 26, and 52 weeks after the final treatment session.

  5. Change From Baseline in Neck Skin Firmness and Elasticity Measured by Cutometer

    Change from baseline in four Cutometer parameters: R0 (skin firmness), R2 (gross elasticity), R5 (net elasticity), and R7 (biological elasticity). Lower R0 values indicate firmer skin, while higher R2, R5, and R7 values indicate greater elasticity.

    Time frame: Baseline and 12, 26, and 52 weeks after the final treatment session.

  6. Incidence of Adverse Events and Device Deficiencies

    Number and percentage of participants experiencing adverse events, including device-related events, serious events, and unanticipated serious device-related events. Events will be characterised by type, severity, seriousness, and relationship to the device or injection procedure. Device deficiencies will be summarised separately.

    Time frame: From the first treatment through 52 weeks after the final treatment session

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2027; primary completion for Aug 2028, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Jul 2027
Primary completionEst.
Aug 2028
CompletionEst.
Jan 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939490
Lead sponsor
Nordberg Medical AB
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jul 2027 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Karina Caramico
Contact
k.caramico@nordbergmedical.com
(+46) 76 336 39 48

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion